Javelin Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for its investigational product candidate, Dyloject (diclofenac sodium) injection, for the management of acute moderate-to-severe pain
Ablynx is expected to receive further milestone payments of E3m from Boehringer Ingelheim, triggered as part of its strategic alliance for the development and commercialisation of nanobodies. Ablynx
Impax Laboratories has entered into a supply agreement with Resolution Chemicals to receive finished Dronabinol product. The company also reported that it has acquired Abbreviated New Drug Applications
Keryx Biopharmaceuticals (Keryx) has received FDA Fast Track designation for KRX-0401 (Perifosine), an oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory
Phosphagenics has initiated Phase 1B clinical trial for its patented Oxycodone/TPM (Targeted Penetration Matrix) transdermal patch systems. The primary objective of the Phase 1B clinical trial is to
PTC Therapeutics (PTC) has received $1m challenge grant award from the National Heart, Lung, and Blood Institute (NHLBI) as part of the National Institutes of Health (NIH). The
Taris Biomedical (Taris) has reported the completion of Phase 1 clinical study of its intravesical drug-device convergence system designed to provide sustained-release of drug directly to the bladder.
Peregrine Pharmaceuticals (Peregrine) has completed patient enrollment in a dose confirmation and dosimetry trial of Cotara in patients with relapsed glioblastoma multiforme (GBM). Cotara is a targeted monoclonal
CytRx has been permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate Arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou
Roche has begun shipping additional quantities of oral suspension (liquid), Tamiflu (oseltamivir phosphate). The added supplies of Tamiflu will begin arriving in pharmacies nationwide and will continue to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.